Results 141 to 150 of about 17,680 (157)

Anti-PD1/PD-L1 Immunotherapy for Non-Small Cell Lung Cancer with Actionable Oncogenic Driver Mutations

International Journal of Molecular Sciences, 2021
Luc Thiberville, Nicolas Piton, Florian Guisier   +2 more
exaly  

Cisplatin nanoparticles possess stronger anti-tumor synergy with PD1/PD-L1 inhibitors than the parental drug

Acta Biomaterialia, 2021
Xuefei Zhang, Na Shen, Xuesi Chen
exaly  

A Pd1–Ps–P1 Feedback Loop Controls Pubescence Density in Soybean

Molecular Plant, 2020
Zhixi Tian, Muhammad Imran, Shulin Liu
exaly  

Anti-PD1 checkpoint inhibitor with or without chemotherapy for patients with recurrent and metastatic nasopharyngeal carcinoma

Translational Oncology, 2021
Qun Zhang, Xiaozhong Chen, Yong-Hong Hua
exaly  

Anti-PD1/PDL1 IgG subclass distribution in ten cancer types and anti-PD1 IgG4 as biomarker for the long time survival in NSCLC with anti-PD1 therapy

Cancer Immunology, Immunotherapy, 2021
Yuankai Shi, Xiaohong Han, Xiaobo Yu
exaly  

The impact of corticosteroid use during anti-PD1 treatment

Journal of Oncology Pharmacy Practice, 2020
Eva Pan
exaly  

BMI1 Inhibition Eliminates Residual Cancer Stem Cells after PD1 Blockade and Activates Antitumor Immunity to Prevent Metastasis and Relapse

Cell Stem Cell, 2020
Cun-Yu Wang
exaly  

Top bar navigation

Frontiers in Cell and Developmental Biology, 2020
Kai Sun, Liping Wang
exaly  

Anti-PD1 rechallenge in combination with anti-angiogenesis or anti-EGFR treatment beyond progression in recurrent/metastatic nasopharyngeal carcinoma patients

Critical Reviews in Oncology/Hematology, 2023
Weixiong Xia, Yan-Qun Xiang
exaly  

Circulating tumour DNA predicts response to anti-PD1 antibodies in metastatic melanoma

Annals of Oncology, 2017
Serigne Lo, Alexander M Menzies, Georgina V. Long   +2 more
exaly